<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND &amp; AIMS: <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">Tumor</z:e>-initiating cells are a subset of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> cells with the ability to form new <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e>; however, they account for less than 0.001% of the cells in colorectal or other types of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>Mesenchymal stem cells (MSCs) integrate into the <z:e sem="disease" ids="C0009404" disease_type="Neoplastic Process" abbrv="">colorectal tumor</z:e> stroma; we investigated their involvement in <z:e sem="disease" ids="C0598935" disease_type="Neoplastic Process" abbrv="">tumor initiation</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS: Human <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> cells, MSCs, and a mixture of both cell types were injected subcutaneously into immunodeficient mice </plain></SENT>
<SENT sid="3" pm="."><plain>We compared the ability of each injection to form <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> and investigated the signaling pathway involved in <z:e sem="disease" ids="C0598935" disease_type="Neoplastic Process" abbrv="">tumor initiation</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS: A small number (≤ 10) of unsorted, CD133⁻, CD166⁻, epithelial cell <z:e sem="disease" ids="C0001511" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">adhesion</z:e> molecule⁻(EpCAM⁻), or CD133⁻/CD166⁻/EpCAM⁻ <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> cells, when mixed with otherwise nontumorigenic MSCs, formed <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> in mice </plain></SENT>
<SENT sid="5" pm="."><plain>Secretion of interleukin (IL)-6 by MSCs increased the expression of CD133 and activation of Janus kinase 2-signal transducer and activator of transcription 3 (STAT3) in the <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> cells, and promoted sphere and <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> formation </plain></SENT>
<SENT sid="6" pm="."><plain>An antibody against IL-6 or lentiviral-mediated transduction of an interfering <z:chebi fb="40" ids="33697">RNA</z:chebi> against IL-6 in MSCs or STAT3 in <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> cells prevented the ability of MSCs to promote sphere formation and <z:e sem="disease" ids="C0598935" disease_type="Neoplastic Process" abbrv="">tumor initiation</z:e> </plain></SENT>
<SENT sid="7" pm="."><plain>CONCLUSIONS: IL-6, secreted by MSCs, signals through STAT3 to increase the numbers of <z:e sem="disease" ids="C0009404" disease_type="Neoplastic Process" abbrv="">colorectal tumor</z:e>-initiating cells and promote <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> formation </plain></SENT>
<SENT sid="8" pm="."><plain>Reagents developed to disrupt this process might be developed to treat patients with <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> </plain></SENT>
</text></document>